David Y. Liu - Feb 15, 2022 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role
Chief Scientific Officer
Signature
/s/ Donald A. Kalkofen, Attorney-in-Fact for David Y. Liu
Stock symbol
PTGX
Transactions as of
Feb 15, 2022
Transactions value $
$0
Form type
4
Date filed
2/17/2022, 06:25 PM
Previous filing
Aug 19, 2021
Next filing
Mar 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTGX Common Stock Award $0 +10K +17.05% $0.00 68.7K Feb 15, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTGX Stock Option (right to buy) Award $0 -60K -50% $0.00 60K Feb 15, 2022 Common Stock 60K $28.73 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents grant of restricted stock units payable solely in common stock that will vest in three annual installments on February 15, 2023, 2024 and 2025.
F2 Includes an aggregate of 403 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2021.
F3 The stock option vests in 48 equal monthly installments following the date of grant.